1 / 8

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021

Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent.<br>For More Information: http://bit.ly/1NnH1v0

richa21
Télécharger la présentation

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence Tobuy this Report Visit http://www.jsbmarketresearch.com

  2. Summary  Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies. g

  3.  Scope The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent. - What are the competitive advantages of the existing novel drugs? - Are these targeted therapies used to the same magnitude in all the countries assessed? - What are the factors contributing to the uptake of these drugs in each country? With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates. g

  4. Reasons to buy This report will enable you to -  • Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options  - Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need  - Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty  - Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action g

  5. Table Of Content 2 Introduction 9 2.1 Disease Introduction 9 2.2 Symptoms 10 2.3 Etiology 10 2.4 Pathophysiology 11 2.5 Epidemiology 12 2.6 Diagnosis and Classification 14 2.7 Prognosis and Disease Staging 16 2.8 Treatment Options 18 2.8.1 Surgery and Radiation Therapy 18 2.8.2 Chemotherapy 19 2.8.3 Hormonal Therapies 19 2.8.4 Targeted Therapies 20 2.8.5 Resistance to Pharmacological Therapies 20 2.9 Treatment Guidelines 21 g

  6. Related Market Research Report • Hormone Refractory Breast Cancer-Pipeline Insights, 2016US • Breast Cancer Imaging Industry 2015 Market Research • Global Breast Cancer Imaging Industry 2015 Market Research ReportReport • Breast Cancer Treatment Drug Companies in China • Breast Cancer Treatment Drug Industry Forecasts - China Focus • Breast Cancer Treatment Drug Markets in China • Metastatic Breast Cancer - Pipeline Review, H1 2015 g

  7. About JSB Market Research JSBMarketResearch.Com is an online repository of an extensive collection of market research reports available online. This online portal contains high quality reports with well-researched and high quality content on a wide range of industries. These market research reportshelp us give a detailed insight into new opportunities in The industry, prevailing market trends, competitor analysis and future prospects. JSB’s reports are developed by the domain experts andpublishers under a closely observed surveillance of industry specialists in Online Database.Therefore, the researched data is well researched, well- organized and matching up to the best standards in the industry. Also JSB’s database consists of detailed insights of the leading players in the global market, products and trends also find latest updates on global conference events. g

  8. To Know More: http://www.jsbmarketresearch.com/healthcare-medical/r-breast-cancer-therapeutics-in-asia-pacific-markets-151132 Contact Details: JSB Market Research Phone: +91 - 998 729 5242 Email - enquiry@jsbmarketresearch.com Website: http://www.jsbmarketresearch.com g

More Related